Phase 2 Brain Cancer Trial, Recruiting NCT07462507 Sponsor: Washington University School of Medicine Condition: Brain Cancer
Back to Brain Cancer

Phase 2 Brain Cancer Trial, Recruiting

NCT07462507
Recruiting Phase 2

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • You are 18 years of age or older, of any race or gender
  • You are able to sign a consent form yourself, or you have a legally authorized person (such as a family member or guardian) who can sign on your behalf
  • You have been diagnosed with a brain or spinal cord tumor (either one that started there or spread from elsewhere in the body) based on medical examination, imaging, or tissue testing
  • Your brain or spinal cord tumor has not yet been treated with radiation therapy

Who may not be able to join:

  • You have had an allergic reaction to the study imaging agent [C-11]-CS1P1 or any of its ingredients
  • You have a condition that makes it unsafe for you to have a PET scan, CT scan, or MRI — for example, certain implanted electronic devices or being unable to lie still for a period of time
  • You have previously received radiation treatment to your head
  • You have severe claustrophobia (fear of enclosed spaces) that would require general anesthesia to complete the scans
  • You are currently pregnant or breastfeeding
  • You have a serious health condition that, in the study doctor's judgment, could put you at greater risk, make it hard for you to complete the study procedures, or affect the study results — for example, advanced kidney or liver failure
  • You have taken part in other research studies involving radioactive materials in the past 12 months, and the combined radiation exposure would exceed the limits allowed by U.S. federal regulations (confirm with trial site)

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 26 July 2026
Phase 2: approximately ~30% of drugs entering this phase reach regulatory approval, based on published industry-wide historical data. This is not specific to this trial.
Phase success rates shown are historical industry-wide averages based on published data. They are not a prediction for this specific trial or your individual situation.

Contact this trial

Principal Investigator: Tammie L.S. Benzinger, M.D., Ph.D., Washington University School of Medicine

Phone: 314-362-6110

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Phase 2
Registry
ClinicalTrials.gov
Start date
16 April 2026
Est. completion
30 June 2031

Where this trial is recruiting

🇺🇸 United States

Primary endpoints

[C-11]CS1P1 Standardized uptake value (SUV) ratio of tumor to non-tumor regions of interest (ROIs)

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 26 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov